

Media Inquires

January 1, 2026 – May 31, 2026

1/15, Alice Tracey, The Capitol Forum, requested communication with [Imprimis](#) between November 13, 2025, and January 15, 2026. On 2/5, reporter asked why an August 2025 accusation against Imprimis cited New Jersey state law violations, if inspections cited were based on New Jersey facilities, and if the Board anticipates reciprocal action against Imprimis in other states. On 3/5, the reporter requested communication with Imprimis between February 3, 2026, and March 3, 2026.

2/19, Julian Gill, *Houston Chronicle*, requested inspection information on [Empower Pharmacy](#). On 3/2, the reporter noted that he will be doing a follow up story to highlight gaps in compounding pharmacy oversight and would like to understand whether California relays adverse event reports from compounding pharmacies to the FDA and does the state routinely collect data on the number and type of drugs that compounding pharmacies distribute.

3/24, Lauren Weber, *The Washington Post*, requested information on peptides, specifically complaints or improper usage.